Griseofulvin (Fulvicin) is an antifungal agent used in the treatment of TINEA infections.

Griseofulvin exhibits effective anti-infective activity in vivo. When administered in conjunction with nocodazole (5 mg/kg), Griseofulvin significantly enhances the efficacy of nocodazole, resulting in the cessation of tumor growth.

In vitro tests have demonstrated that the minimum inhibitory concentration (MIC) of Griseofulvin against various dermatophytes ranges between 0.14 to 0.6 µg/mL. Griseofulvin's primary mechanism of action on cellular mitosis is the disassembly of spindle microtubules. Additionally, Griseofulvin has the capacity to induce chromosomal structural abnormalities in mammalian cells. It is effective in combating different types of skin fungi, including species from the genera Microsporum, Trichophyton, and Epidermophyton. However, it is not sensitive to other fungi, such as Scopulariopsis and Hendersonula, and has almost no effect on yeasts.

The cells (5× 103/mL) are incubated in triplicate in a 96-well plate in the presence or absence of indicated concentration of Griseofulvin in a final volume of 0.2 mL for different time intervals at 37 ℃. Thereafter, 20 μL MTT solution (5 mg/mL in PBS) is added to each well. After a 2-hour incubation at 37 ℃, 0.1 mL lysis buffer (20% SDS, 50% dimethylformamide) is added, incubation is continued overnight at 37 ℃, and then the optical density at 570 nm is measured by plate reader. (Only for Reference)

DMSO: 62.5 mg/mL (177.17 mM), Sonication is recommended.

Ethanol: < 1 mg/mL (insoluble or slightly soluble)

H2O: < 1 mg/mL (insoluble or slightly soluble)

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.67 mM), Sonication is recommended.